A short overview of dual targeting HDAC inhibitors

被引：0
作者：
Liu, Wen-Bo [1 ]
Song, Jian [1 ]
Zhang, Sai-Yang [1 ,2 ]
机构：
[1] Zhengzhou Univ, Sch Basic Med Sci, Zhengzhou 450001, Peoples R China
[2] State Key Lab Esophageal Canc Prevent & Treatment, Zhengzhou, Peoples R China
来源：
FUTURE MEDICINAL CHEMISTRY | 2025年 / 17卷 / 01期
基金：
中国国家自然科学基金;
关键词：
HDACs; HDAC inhibitors; dual targeting; drug resistance; HISTONE DEACETYLASE INHIBITORS;
D O I：
10.1080/17568919.2024.2437975
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
引用
收藏
页码：5 / 7
页数：3
相关论文
共 21 条
[1]   Polypharmacology: Challenges and Opportunities in Drug Discovery [J].
Anighoro, Andrew ;
Bajorath, Juergen ;
Rastelli, Giulio .
JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (19) :7874-7887
[2]   The application of PROTAC in HDAC [J].
Chen, Shaoting ;
Zheng, Yuxiang ;
Liang, Benji ;
Yin, Yudong ;
Yao, Jian ;
Wang, Quande ;
Liu, Yanghan ;
Neamati, Nouri .
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2023, 260
[3]   Histone deacetylase inhibitors: Overview and perspectives [J].
Dokmanovic, Milos ;
Clarke, Cathy ;
Marks, Paul A. .
MOLECULAR CANCER RESEARCH, 2007, 5 (10) :981-989
[4]   Advances in dual-targeting inhibitors of HDAC6 for cancer treatment [J].
Gu, Zhicheng ;
Lin, Shuxian ;
Yu, Junhui ;
Jin, Fei ;
Zhang, Qingqing ;
Xia, Keli ;
Chen, Lei ;
Li, Yan ;
He, Bin .
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2024, 275
[5]   A phase 1 trial of abexinostat with ibrutinib in relapsed/refractory mantle cell lymphoma and non-germinal center diffuse large B cell lymphoma [J].
Gurumurthi, Ashwath ;
Bantilan, Kurt S. ;
Hamlin, Paul A. ;
Kumar, Anita ;
Matasar, Matthew ;
Zhu, Menglei ;
Joseph, Ashlee ;
Castro, Ali ;
Biggar, Erin ;
Salles, Gilles ;
Zelenetz, Andrew D. ;
von Keudell, Gottfried .
LEUKEMIA & LYMPHOMA, 2024, 65 (14) :2224-2227
[6]   Proteomics analysis of histone deacetylase inhibitor-resistant solid tumors reveals resistant signatures and potential drug combinations [J].
Hao, Bing-bing ;
Ma, Ke ;
Xu, Jun-yu ;
Fan, Ru-feng ;
Zhao, Wen-si ;
Jia, Xing-long ;
Zhai, Lin-hui ;
Lee, Sangkyu ;
Xie, Dong ;
Tan, Min-jia .
ACTA PHARMACOLOGICA SINICA, 2024, 45 (06) :1305-1315
[7]   Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma [J].
Janku, Filip ;
Park, Haeseong ;
Call, S. Greg ;
Madwani, Kiran ;
Oki, Yasuhiro ;
Subbiah, Vivek ;
Hong, David S. ;
Naing, Aung ;
Velez-Bravo, Vivianne M. ;
Barnes, Tamara G. ;
Hagemeister, Fredrick B. ;
Falchook, Gerald S. ;
Karp, Daniel D. ;
Wheler, Jennifer J. ;
Piha-Paul, Sarina A. ;
Garrido-Laguna, Ignacio ;
Shpall, Elizabeth J. ;
Fayad, Luis E. ;
Neelapu, Sattva S. ;
Meric-Bernstam, Funda ;
Kurzrock, Razelle ;
Fanale, Michelle A. .
CLINICAL CANCER RESEARCH, 2020, 26 (21) :5579-5587
[8]   Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial [J].
Jiang, Zefei ;
Li, Wei ;
Hu, Xichun ;
Zhang, Qingyuan ;
Sun, Tao ;
Cui, Shude ;
Wang, Shusen ;
Ouyang, Quchang ;
Yin, Yongmei ;
Geng, Cuizhi ;
Tong, Zhongsheng ;
Cheng, Ying ;
Pan, Yueyin ;
Sun, Yuping ;
Wang, Hong ;
Ouyang, Tao ;
Gu, Kangsheng ;
Feng, Jifeng ;
Wang, Xiaojia ;
Wang, Shubin ;
Liu, Tianshu ;
Gao, Jinghua ;
Cristofanilli, Massimo ;
Ning, Zhiqiang ;
Lu, Xianping .
LANCET ONCOLOGY, 2019, 20 (06) :806-815
[9]   Targeting histone deacetylases for cancer therapy: Trends and challenges [J].
Liang, Tao ;
Wang, Fengli ;
Elhassan, Reham M. ;
Cheng, Yongmei ;
Tang, Xiaolei ;
Chen, Wengang ;
Fang, Hao ;
Hou, Xuben .
ACTA PHARMACEUTICA SINICA B, 2023, 13 (06) :2425-2463
[10]   Epigenetic modification enzymes: catalytic mechanisms and inhibitors [J].
Lu, Duo .
ACTA PHARMACEUTICA SINICA B, 2013, 3 (03) :141-149
123